-
Expert comment: AMG 510 KRAS inhibitor trial results – ‘A good start’ (with Colin Lindsay)
- 2019/10/07
- 再生時間: 4 分
- ポッドキャスト
-
サマリー
あらすじ・解説
Colin Lindsay discusses the trial results for AMG 510 – a novel inhibitor targeting the KRAS G12C mutation – in patients with locally advanced or metastatic non-small-cell lung cancer.
Find more on Medicine Matters oncology
More from WCLC 2019